Retatrutide
20mg

Retatrutide (LY-3437943) is a novel triple-action receptor agonist peptide developed by Eli Lilly. It simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism creates synergistic effects — GLP-1 reduces appetite and improves blood sugar control, GIP enhances insulin response and fat metabolism, while glucagon activation increases energy expenditure and promotes liver fat reduction.

Our Retatrutide 20mg vials are manufactured to research-grade standards with a purity of ≥99%, verified through independent third-party HPLC (High-Performance Liquid Chromatography) and mass spectrometry testing. Each order includes a Certificate of Analysis (CoA) documenting the exact purity, identity confirmation, and endotoxin levels of your specific batch.

For optimal stability, Retatrutide should be stored as a lyophilized (freeze-dried) powder at -20°C for long-term storage, or at 2-8°C (standard refrigerator temperature) for short-term storage up to several weeks. Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2-8°C and used within 4 weeks. Avoid repeated freeze-thaw cycles and protect from direct light exposure.

In the landmark Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of Retatrutide achieved an average weight reduction of approximately 24% at 48 weeks. The more recent TRIUMPH-4 Phase 3 trial demonstrated an average weight loss of 28.7% at 68 weeks. Additional benefits include significant reductions in liver fat, improvements in cardiovascular risk markers, and meaningful HbA1c reductions in participants with Type 2 diabetes.

While Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist and Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist, Retatrutide is the first triple-agonist targeting GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor activation provides unique benefits including increased resting energy expenditure and enhanced liver fat reduction. Clinical data suggests Retatrutide may produce greater weight loss than both alternatives.

In clinical trials, Retatrutide was administered as a once-weekly subcutaneous injection with a gradual dose escalation protocol. The titration typically starts at a lower dose and increases over several weeks to minimize gastrointestinal side effects. This product is sold strictly for research purposes. Please consult the relevant clinical literature and your institutional guidelines for specific dosing protocols.

Yes, we offer significant volume discounts. Our standard pricing tiers are: 1 vial at $150 each, 5 vials at $125 each ($625 total, saving $125), and 10 vials at $90 each ($900 total, saving $600). For orders exceeding 10 vials or for institutional/laboratory accounts, please contact us directly for custom wholesale pricing.

We accept Bitcoin (BTC) for fast, private transactions, as well as bank transfers. For Bitcoin, simply send payment to the wallet address provided on our payment page. For bank transfer details, please contact [email protected]. You can also reach us via Signal (@OzR3ta.33) or Threema (64S5X96V).

All orders are shipped in temperature-controlled, discreet packaging to maintain product integrity. Standard shipping is free and typically takes 3-5 business days. Express shipping is available for $10 with 2-3 business day delivery. Orders of 10+ vials qualify for free express shipping. We ship to most regions and provide tracking information for every order.